Etoposide capsules in one study were administered for 5 days to a total dose of 800 mg/m2. A response rate of 70% and a median survival of 9.5 months was seen, result comparable with the efficacy of more toxic and complicated chemotherapy regimens. So can we rethink to give oral etoposide as a monotherapy in small cell lung cancer patients with poor performance status?
Dear Dr. Maji
Plutinum-etoposide regimen in patient with extensive SCLC remains the standard front line thrapy, however there are sdtudies about oral using of irinotecan and topotecan (i.e. cisplatin/irinotecan and cisplatin/topotecan).
I am totally agreed with you Dr Seyyed Mortaza Haggoo...but here i am givin stress on monotherapy with oral etoposide not all the platinum compounds...what is your idea about it and what is the indication ?
Dear Dr. Maji
I searched evidence about oral etoposide indication again during past week, almost all of the investigators believed that oral etoposide monotherapy is'nt good selection for SCLC patients, but there was an evidence that was suggested oral etoposide for eldery patients and believed that this chemotherapy regimen had less side effect and patient had a good overall survival (13.4 m). After this review, I suggest combination chemotherapy that I explained about it in the previous answer for your question.
Best regards
thank you very much Dr. Haggoo for your sincere opinion...please cite those articles here
- Badges
- Science topic
- Similar topics
- Medicine
- Disease
- Infectious Diseases